The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results Meeting Abstract
| Authors: | Krop, I.; Johnston, S.; Mayer, I. A.; Dickler, M.; Ganju, V.; Forero-Torres, A.; Melichar, B.; Morales, S.; de Boer, R.; Gendreau, S.; Derynck, M.; Lackner, M.; Spoerke, J.; Yeh, R. F.; Levy, G.; Ng, V.; O'Brien, C.; Savage, H.; Xiao, Y. Y.; Wilson, T.; Lee, S. C.; Petrakova, K.; Vallentin, S.; Yardley, D.; Ellis, M.; Piccart, M.; Perez, E. A.; Winer, E.; Schmid, P. |
| Abstract Title: | The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results |
| Meeting Title: | 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 75 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2014 Dec 9-13 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-01 |
| Language: | English |
| ACCESSION: | WOS:000356730200012 |
| DOI: | 10.1158/1538-7445.sabcs14-s2-02 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: S2-02 -- Source: Wos |
